MacuLogix articles
February is National Age-Related Macular Degeneration (AMD) and Low Vision Month. This disease is the leading cause of blindness, and its prevalence is expected to soar as the world’s population ages, leading to an overwhelming projected demand for AMD care by 2050. AMD Awareness Month is a great time to shine a light on this disease and its impact on patients and their families.
When automated dark adaptometry was first commercialized, many of us had more questions than answers with regard to using this information for detecting AMD and monitoring disease progression. But with more than seven years of practical in-office experience performing dark adaptation testing on thousands of patients, the tables have turned. This technology offers a safety net for providers and patients—not to mention the potential public health benefits tha